Context

Ottobock successfully completed its Initial Public Offering on the Frankfurt Stock Exchange, marking the largest German IPO of 2025. The shares were priced at €66.00, with the first trading price reaching €72.00 (a 9% premium). At the issue price, the market capitalization stood at €4.2 billion, rising to €4.6 billion upon listing. The strategic rationale for the IPO was to raise gross proceeds to deleverage the balance sheet and accelerate investments in "future technologies," such as AI-integrated bionics and exoskeleton research. Additionally, the capital will fund targeted acquisitions in the fragmented Patient Care and components sectors. The deal marks a milestone in the company’s history, professionalizing its capital structure while providing an exit path for previous minority stakeholders and securing a long-term capital base for global expansion.

Target

Ottobock is the global market leader in wearable human bionics and prosthetics. Its business model integrates the development and manufacturing of high-tech mobility solutions—including bionic prostheses, braces, and wheelchairs—with a vast global "Patient Care" network of over 400 fitting centers. The company’s value proposition centers on restoring human mobility through innovation, such as the microprocessor-controlled C-Leg and the Genium bionic knee. Strategically, Ottobock operates a vertically integrated model, capturing value from R&D and component manufacturing to direct clinical service delivery. With over 9,300 employees, the firm has evolved from a traditional family business into a data-driven medtech powerhouse, focusing on digitalizing the orthopedic fitting process and expanding its presence in emerging markets.